search
Back to results

Intervention Study in Prostate Cancer Patients Undergoing Radiotherapy (MicroStyle)

Primary Purpose

Prostate Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
INTERVENTION GROUP
Sponsored by
European Institute of Oncology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Prostate Cancer focused on measuring Lifestyle, microbiota, diet, radiotherapy, physical activity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • men aged 18 or older
  • candidates for a prostate curative treatment with RT (which includes exclusive RT +/-hormone therapy, surgery followed by RT +/- hormone therapy) AND
  • good performance status (ECOG < 2) AND
  • written informed consent obtained AND
  • willing to be randomized to either group, AND
  • willing to wear the wrist-based activity monitor during the 6-month study period.

Exclusion Criteria:

  • BMI <18.5 AND
  • extra pelvic lymph node involvement or metastasis and severe medical condition(s) that would prevent optimal participation in the physical activities prescribed AND
  • Malnutrition Universal Screening Tool (MUST) ≥ 2. It considers body mass index, weight change and acute disease effect equally and determines a malnutrition risk score. A score ≥2 identify a patient at high risk of malnutrition AND
  • investigator does not approve participation in the study in case of severe clinical condition that would prevent optimal participation in the physical activities prescribed; any other severe medical condition or advanced age impeding the patient to adhere at the planned study follow-up period.

Sites / Locations

  • European Institute of OncologyRecruiting
  • Istituto Nazionale Tumori-IRCCS-Fondazione G. PascaleRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention group (IG)

Control group (CG)

Arm Description

Participants randomized to the IG will be offered an individualized counseling during cancer treatments that includes both a dietary and physical activity suggestions to control side effects, to cope with feelings of anxiety or depression and to improve quality of life.

Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6-month period.

Outcomes

Primary Outcome Measures

Change in adherence to a healthy lifestyle score
The score will be computed using BMI, level of physical activity and food consumptions according the standardized system based on the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) recommendations (Shams-White et al, 2019). The score will range from 0 (minimal adherence) to 7 (maximal adherence).

Secondary Outcome Measures

The effects of the interventions on serum biomarkers
differences by arms in changes of Prostate-specific antigen (PSA) (mcg/L) and 25-hydroxyvitamin D (ng/mL) compared to the baseline.
Change in body composition
change in body composition assessed at all visits using bioelectrical impedance vector analysis (BIVA) compared to the baseline
Change in quality of Life
change in quality of life, measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire which consists of 39 items. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores. Higher scores represent better QoL.
Change in Dietary intake
change in daily or weekly intake of the main food groups included in a validated short self-administered questionnaire over the previous months and the change over the study
change in the level of physical activity
The International Physical Activity Questionnaire (IPAQ)- Short Form will be used. It obtains information about how much time is spent while walking and in moderate and vigorous activities and sitting duration in the last 7 days. The questionnaire records the activity of four intensity levels: 1) vigorous-intensity activity, 2) moderate-intensity activity, 3) walking, and 4) sitting. Durations are multiplied by known metabolic equivalent of tasks (METs) per activity and the results for all items are summed for the overall physical activity score. Scores for walking and for moderate and vigorous activities are sums of corresponding item scores. The change in the level of physical activity will be estimated and compared to the baseline.
Change in acute and late toxicity
change in toxicity according to Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) scoring criteria. It consists of a scoring range from 0 to 5 where 0 means an absence of radiation effects and 5 means the effects led to death, compared to the baseline.

Full Information

First Posted
September 14, 2021
Last Updated
June 27, 2023
Sponsor
European Institute of Oncology
Collaborators
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
search

1. Study Identification

Unique Protocol Identification Number
NCT05155618
Brief Title
Intervention Study in Prostate Cancer Patients Undergoing Radiotherapy
Acronym
MicroStyle
Official Title
Intervention Study on Life Style and Microbiota in Prostate Cancer Patients Undergoing Radiotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 8, 2021 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Institute of Oncology
Collaborators
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Microstyle study aims to evaluate the effect of a 6-month intervention in a group of prostate cancer patients undergoing radiotherapy. Intervention is designed to control side effects and to improve adherence to a healthy lifestyle (diet and increase level of physical activity and decreased sedentary time) measured by the change in adherence to a healthy lifestyle score. The impact of the intervention on toxicity and gastrointestinal symptomatology will be measured by a mediation framework analysis. This approach allows investigating how microbiome may mediate effect of treatment. It will be also assessed the change in microbiome in relation to the change in cytokines/ adipokines in association with early and late toxicity.
Detailed Description
MicroStyle study is a randomized two-arm crossover clinical trial. Study participants will be recruited among men undergoing radiotherapy (RT) in two centers (Milan and Naples). The study will be conducted over a three-year period, during which patients will receive a 6-month intervention and will be followed for other 6 months. The crossover design is used to reduce drop-out and to offer all patients the same opportunities, and also to evaluate the effect of the intervention after 6-month from RT when patients should have recreated a healthier microbiome and have less treatment side effects. Three hundred patients will be enrolled over the study period and randomized in two arms: Intervention Group (IG) and Control Group (CG). Participants allocated to the IG will meet a dietitian and a physiotherapist before RT to receive personalized diet and exercise recommendations, according to their health status, to improve overall lifestyle and reduce side effects (bowel and/or urinary problems). The dietitian will give indication to limit the gastrointestinal side effects reducing consumption of foods rich in fiber, lactose and simple sugars, and the physiotherapist will set individualized goals based on capabilities, lifestyle pattern and preferences to increase physical activity and to reduce sedentary time. Moreover, the physiotherapist will provide specific indication to improve genitourinary health to reduce urinary incontinence that follows prostate treatments, erectile dysfunction and pelvic pain due to muscle spasm. All participants will be given a pedometer device (steps counter) in order to monitor and interfere (in the intervention group) with participants' physical activity and sedentary time. Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6 months period. Microstyle study foresee a 6-month intervention followed by 6-months of follow-up, over a period of 12 months for the intervention group (IG) while the control group (CG) will start the intervention 6 months after RT and they will follow-up for other 6 months over a period of 18 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
Lifestyle, microbiota, diet, radiotherapy, physical activity

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Supportive Care: protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group (IG)
Arm Type
Experimental
Arm Description
Participants randomized to the IG will be offered an individualized counseling during cancer treatments that includes both a dietary and physical activity suggestions to control side effects, to cope with feelings of anxiety or depression and to improve quality of life.
Arm Title
Control group (CG)
Arm Type
No Intervention
Arm Description
Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6-month period.
Intervention Type
Procedure
Intervention Name(s)
INTERVENTION GROUP
Other Intervention Name(s)
IG
Intervention Description
Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
Primary Outcome Measure Information:
Title
Change in adherence to a healthy lifestyle score
Description
The score will be computed using BMI, level of physical activity and food consumptions according the standardized system based on the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) recommendations (Shams-White et al, 2019). The score will range from 0 (minimal adherence) to 7 (maximal adherence).
Time Frame
It will be assessed at the end of the 6-month intervention
Secondary Outcome Measure Information:
Title
The effects of the interventions on serum biomarkers
Description
differences by arms in changes of Prostate-specific antigen (PSA) (mcg/L) and 25-hydroxyvitamin D (ng/mL) compared to the baseline.
Time Frame
6-month - 12-month and 18-month (only for the CG)
Title
Change in body composition
Description
change in body composition assessed at all visits using bioelectrical impedance vector analysis (BIVA) compared to the baseline
Time Frame
6-month - up to 30 days - 12-month and 18-month (only for the CG)
Title
Change in quality of Life
Description
change in quality of life, measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire which consists of 39 items. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores. Higher scores represent better QoL.
Time Frame
6-month - 12-month and 18-month (only for the CG)
Title
Change in Dietary intake
Description
change in daily or weekly intake of the main food groups included in a validated short self-administered questionnaire over the previous months and the change over the study
Time Frame
6-month - up to 30 days - 12-month and 18-month (only for the CG)
Title
change in the level of physical activity
Description
The International Physical Activity Questionnaire (IPAQ)- Short Form will be used. It obtains information about how much time is spent while walking and in moderate and vigorous activities and sitting duration in the last 7 days. The questionnaire records the activity of four intensity levels: 1) vigorous-intensity activity, 2) moderate-intensity activity, 3) walking, and 4) sitting. Durations are multiplied by known metabolic equivalent of tasks (METs) per activity and the results for all items are summed for the overall physical activity score. Scores for walking and for moderate and vigorous activities are sums of corresponding item scores. The change in the level of physical activity will be estimated and compared to the baseline.
Time Frame
6-month and 12-month (only for the CG)
Title
Change in acute and late toxicity
Description
change in toxicity according to Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) scoring criteria. It consists of a scoring range from 0 to 5 where 0 means an absence of radiation effects and 5 means the effects led to death, compared to the baseline.
Time Frame
6-month - up to 30 days - 12-month and 18-month (only for the CG)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: men aged 18 or older candidates for a prostate curative treatment with RT (which includes exclusive RT +/-hormone therapy, surgery followed by RT +/- hormone therapy) AND good performance status (ECOG < 2) AND written informed consent obtained AND willing to be randomized to either group, AND willing to wear the wrist-based activity monitor during the 6-month study period. Exclusion Criteria: BMI <18.5 AND extra pelvic lymph node involvement or metastasis and severe medical condition(s) that would prevent optimal participation in the physical activities prescribed AND Malnutrition Universal Screening Tool (MUST) ≥ 2. It considers body mass index, weight change and acute disease effect equally and determines a malnutrition risk score. A score ≥2 identify a patient at high risk of malnutrition AND investigator does not approve participation in the study in case of severe clinical condition that would prevent optimal participation in the physical activities prescribed; any other severe medical condition or advanced age impeding the patient to adhere at the planned study follow-up period.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara Gandini, MSc
Phone
00390257489819
Email
sara.gandini@ieo.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Gandini, MSc
Organizational Affiliation
Department of Experimental Oncology, IEO, Milan
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Valentina Borzillo, MD
Organizational Affiliation
Department of Radiation Oncology, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli
Official's Role
Principal Investigator
Facility Information:
Facility Name
European Institute of Oncology
City
Milan
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Gandini
Phone
0039 02 57489819
Email
sara.gandini@ieo.it
Facility Name
Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale
City
Naples
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valentina Borzillo
Phone
003908159031764
Email
v.borzillo@istitutotumori.na.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35854230
Citation
Gnagnarella P, Marvaso G, Jereczek-Fossa BA, de Cobelli O, Simoncini MC, Nevola Teixeira LF, Sabbatini A, Pravettoni G, Johansson H, Nezi L, Muto P, Borzillo V, Celentano E, Crispo A, Pinto M, Cavalcanti E, Gandini S; MicroStyle Collaborative Group. Life style and interaction with microbiota in prostate cancer patients undergoing radiotherapy: study protocol for a randomized controlled trial. BMC Cancer. 2022 Jul 19;22(1):794. doi: 10.1186/s12885-022-09521-4.
Results Reference
derived

Learn more about this trial

Intervention Study in Prostate Cancer Patients Undergoing Radiotherapy

We'll reach out to this number within 24 hrs